Navigation Links
Expensive, Drug-Emitting Stents May Be Overused: Study
Date:7/9/2012

MONDAY, July 9 (HealthDay News) -- The use of drug-coated stents to keep arteries open after an artery-clearing procedure varies greatly among U.S. surgeons, and those who do insert the devices may not need to in patients at low risk of re-clogged arteries, a new study finds.

The research suggests that surgeons could use the stents somewhat less frequently, saving the American health care system tens of millions of dollars while only slightly increasing the number of patients suffering from re-clogged arteries.

The study was released online July 9 in advance of publication in an upcoming print issue of the journal Archives of Internal Medicine.

The finding is related to a specific kind of stent used in angioplasties, which are procedures designed to clear clogged arteries. Unlike some stents, which are simply metal, these "drug-eluting" stents release medications designed to prevent further clogging.

The study was led by Dr. John Spertus, clinical director of Outcomes Research at Saint Luke's Mid America Heart Institute in Kansas City. His team examined the medical records of more than 1.5 million patients who underwent angioplasties to see what happened to them. The researchers found that many doctors used the stents regardless of the estimated risk that the patients' vessels would re-clog.

The American health care system could save more than $200 million a year, the researchers estimated, if surgeons used the drug-releasing stents half as much in patients at low risk of future artery clogging. This reduction in usage was estimated to increase the rate of re-clogged arteries by about 0.5 percent, according to the report.

Commenting on the study, Dr. David L. Brown, a cardiologist and professor of medicine at Stony Brook University, said that the study findings are valid and reflect "the irrational overuse of new technology."

"Unfortunately, this study illustrates yet another example of cardiologists running up the costs of health care rather than leading in controlling costs without compromising outcomes," he said. "Hopefully this paper will stimulate changes in practice by interventional cardiologists."

As for patients, Brown said they "should understand that many of them will not benefit from drug-eluting stents. Furthermore, drug-eluting stents come with a financial cost as well as the risk and additional cost of prolonged dual antiplatelet therapy. They should discuss the risks and benefits of drug-eluting stents before any proposed stent procedure."

More information

For more about angioplasty, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: David L. Brown, M.D., cardiologist and professor of medicine, Stony Brook University, N.Y.; Saint Luke's Mid America Heart Institute, news release, July 9, 2012; July 9, 2012, Archives of Internal Medicine, online


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Dissolvable Heart Artery Stents Appear Safe in Study
2. Study Suggests Vaccine May Help Kids With Brain Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
5. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
6. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
7. No Added Cancer Risk From Hip Replacement Materials: Study
8. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
9. Early Study Finds Some Promise for Lung Cancer Vaccine
10. Narcissists Often Ace Job Interviews, Study Finds
11. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Expensive, Drug-Emitting Stents May Be Overused: Study 
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the Cowen and Company 37 ... Marriott Copley Place on Tuesday, March 7, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
Breaking Medicine Technology: